# Revance Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/revance-therapeutics

- Industry: Biotechnology
- Headquarters: Nashville, US
- Website: www.revance.com
- Total disclosed funding: $168M
- Latest round: Series E (Apr 2, 2013)
- Investors on record: 12

## About

Revance Therapeutics, Inc. is a US-based biotechnology company dedicated to developing innovative aesthetics and skincare solutions that enhance appearance and skin health through advanced therapeutic products.Revance Therapeutics, Inc. focuses on the development of therapeutic and aesthetic products. Founded in 1999 and headquartered in Nashville, US, Revance has conducted 17 deals to date, with the most recent funding round occurring on June 18, 2014. The latest round, an Add-on, Public to Private, and Trade Sale, raised USD 924.00 mn, bringing the total capital raised to USD 200.00 mn. Mark Foley serves as the CEO of the company.Revance Therapeutics, Inc. specializes in innovative aesthetics and skincare solutions, focusing on products that enhance both appearance and skin health for various age groups. The company's flagship offerings include DAXXIFY® (DaxibotulinumtoxinA-lanm), a peptide-formulated neuromodulator approved for the temporary improvement of moderate to severe glabellar lines and treatment of cervical dystonia in adults. Additionally, Revance markets the Teoxane RHA® Collection, which features hyaluronic acid fillers designed for treating dynamic facial lines and wrinkles through advanced Preserved Network Technology. Their product suite also includes SkinPen® Precision, the leading microneedling brand in the U.S., and BIOJUVE®, which utilizes clinically proven living microbe technology. Revance's products are distributed across 60 countries, including major markets such as the United States, Canada, and Europe, addressing the needs of both patients seeking aesthetic enhancements and healthcare providers.Revance generates revenue primarily through direct sales of its specialized aesthetic products and therapeutic solutions to healthcare professionals, clinics, and distributors. In 2023, Revance reported a revenue of USD 234.04 mn alongside an EBITDA of USD -307.13 mn. The company employs a B2B model, supplying products like DAXXIFY® and the Teoxane RHA® Collection to aesthetic practices and dermatology clinics, which then offer these treatments to their end customers. Revenue is realized upon the delivery of products to these clinics, with repeat purchases expected as practitioners restock based on patient demand and treatment cycles.Revance Therapeutics, Inc. has plans to introduce new products and expand into new markets. The company is leveraging its most recent funding round from June 2014 to support these initiatives. Following the private placement that raised USD 924.00 mn, Revance aims to launch additional products in the aesthetic space and explore opportunities for market entry in regions such as Asia-Pacific and Latin America, targeting the next few years to establish a presence in these growing markets.

## Funding rounds

- Series E, Apr 2, 2013, $33M — Delphi Ventures, Essex Woodlands, Technology Partners, Shepherd Ventures, Pac-Link, Vivo Capital, SG Growth Capital, NovaQuest Capital Management, Palo Alto Investors
- Series D, Jun 10, 2011, $45M — Essex Woodlands, Technology Partners, Shepherd Ventures, Pac-Link, Vivo Capital, NovaQuest Capital Management, Palo Alto Investors, CNF Investments, Essex Capital Corporation
- Series D, Dec 22, 2009, $26M — Essex Woodlands, Technology Partners, Shepherd Ventures, Pac-Link, Vivo Capital, SG Growth Capital, Palo Alto Investors
- Series C, May 12, 2008, $8M — Essex Woodlands, Technology Partners, Shepherd Ventures, Pac-Link, Vivo Capital, SG Growth Capital, Palo Alto Investors, Medicis Pharmaceutical Corporation
- Series C, Dec 12, 2007, $43M — Essex Woodlands, Technology Partners, Shepherd Ventures, Vivo Capital, Palo Alto Investors, Medicis Pharmaceutical Corporation
- Series B, Apr 27, 2004, $13M — Essex Woodlands, Vivo Capital, Technology Partners

## Investors

- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series B, Series C, Series D, Series E
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series B, Series C, Series D, Series E
- Technology Partners — Series B, Series C, Series D, Series E
- Shepherd Ventures (https://capitalatlas.ai/funds/shepherd-ventures) — Series C, Series D, Series E
- Palo Alto Investors (https://capitalatlas.ai/funds/palo-alto-investors) — Series C, Series D, Series E
- Medicis Pharmaceutical Corporation — Series C
- Pac-Link (https://capitalatlas.ai/funds/pac-link) — Series C, Series D, Series E
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series C, Series D, Series E
- NovaQuest Capital Management (https://capitalatlas.ai/funds/novaquest-capital-management) — Series D, Series E
- CNF Investments (https://capitalatlas.ai/funds/cnf-investments) — Series D
- Essex Capital Corporation — Series D
- Delphi Ventures (https://capitalatlas.ai/funds/delphi-ventures) — Series E